ReviewFrontiers in gastroenterology (Lausanne, Switzerland)2026
Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms.
Review in Frontiers in gastroenterology (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases, encompassing Crohn's disease and ulcerative colitis, are chronic inflammatory disorders of the gastrointestinal tract. The recent expansion in advanced therapy options has not dramatically altered the ceiling of treatment efficacy. Therapeutic drug monitoring (TDM) of the serum drug levels and anti-drug antibodies has the potential to optimise treatment efficacy through dose adjustment. TDM has shown benefit with purine analogues and anti-tumour necrosis factor (TNF) therapy. Less is known about the role of TDM in non-anti-TNF advanced therapies. This review summarises the current evidence base for TDM in non-anti-TNF advanced therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.